Anna Jerkeman

840 total citations
10 papers, 85 citations indexed

About

Anna Jerkeman is a scholar working on Epidemiology, Hepatology and Pathology and Forensic Medicine. According to data from OpenAlex, Anna Jerkeman has authored 10 papers receiving a total of 85 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Epidemiology, 5 papers in Hepatology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Anna Jerkeman's work include Hepatitis C virus research (5 papers), HIV, Drug Use, Sexual Risk (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). Anna Jerkeman is often cited by papers focused on Hepatitis C virus research (5 papers), HIV, Drug Use, Sexual Risk (5 papers) and Liver Disease Diagnosis and Treatment (4 papers). Anna Jerkeman collaborates with scholars based in Sweden, Bulgaria and United States. Anna Jerkeman's co-authors include Marianne Alanko Blomé, Per Björkman, Anders Håkansson, Martin Lagging, Erik Berntorp, Ulla Hedner, Soo Aleman, Jan Astermark, Martin Kåberg and Carl‐Gustav Olsson and has published in prestigious journals such as PLoS ONE, Gastrointestinal Endoscopy and Drug and Alcohol Dependence.

In The Last Decade

Anna Jerkeman

10 papers receiving 84 citations

Peers

Anna Jerkeman

EPIDE

HEPAT

PHEOH

TOXIC

CCM

Lydjie Tremblay Canada

Pedro Antônio Muniz Ferreira Brazil

M. Bernal Spain

Phillip Tarkington United States

Juhi Moon United States

Aziz Rezapour Iran

Ruth Jimbo-Sotomayor Ecuador

Anna Kyriakoudi Greece

As’ad E. Bhorat United States

Christopher Barbara Malta

Lydjie Tremblay Canada

Anna Jerkeman

30 ×0.5

EPIDE

28 ×0.8

HEPAT

7 ×0.4

PHEOH

1 ×0.1

TOXIC

0 ×0.0

CCM

Citations per year, relative to Anna Jerkeman Anna Jerkeman (= 1×) peers Lydjie Tremblay

Countries citing papers authored by Anna Jerkeman

Since Specialization

Citations

This map shows the geographic impact of Anna Jerkeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Jerkeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Jerkeman more than expected).

Fields of papers citing papers by Anna Jerkeman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Jerkeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Jerkeman. The network helps show where Anna Jerkeman may publish in the future.

Co-authorship network of co-authors of Anna Jerkeman

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Jerkeman. A scholar is included among the top collaborators of Anna Jerkeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Jerkeman. Anna Jerkeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Blomé, Marianne Alanko, et al.. (2021). Hepatitis C treatment at a Swedish needle exchange program, a successful model of care – the ACTIONNE study. International Journal of Drug Policy. 96. 103407–103407. 7 indexed citations

2.

Håkansson, Anders, Martin Kåberg, Anna Jerkeman, et al.. (2021). Mortality among amphetamine users with hepatitis C virus infection: A nationwide study. PLoS ONE. 16(6). e0253710–e0253710. 4 indexed citations

3.

Blach, Sarah, Marianne Alanko Blomé, Ann‐Sofi Duberg, et al.. (2021). Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19. Liver International. 41(9). 2024–2031. 12 indexed citations

4.

Kåberg, Martin, Simon B. Larsson, Anna Jerkeman, et al.. (2020). High risk of non-alcoholic liver disease mortality in patients with chronic hepatitis C with illicit substance use disorder. Scandinavian Journal of Gastroenterology. 55(5). 574–580. 1 indexed citations

5.

Thorlacius, Henrik, et al.. (2018). Colorectal malakoplakia in a patient with hypogammaglobulinemia. Gastrointestinal Endoscopy. 88(3). 563–565. 1 indexed citations

6.

Jerkeman, Anna, et al.. (2018). Mortality and causes of death among people who inject amphetamine: A long-term follow-up cohort study from a needle exchange program in Sweden. Drug and Alcohol Dependence. 188. 274–280. 25 indexed citations

7.

Jerkeman, Anna, Anders Håkansson, Rebecca Rylance, et al.. (2016). Death from liver disease in a cohort of injecting opioid users in a Swedish city in relation to registration for opioid substitution therapy. Drug and Alcohol Review. 36(3). 424–431. 9 indexed citations

8.

Jerkeman, Anna, Gunnar Norkrans, Christer Lidman, et al.. (2014). Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities – completion rates and efficacy. European Journal of Gastroenterology & Hepatology. 26(5). 523–531. 9 indexed citations

9.

Jerkeman, Anna, Johan Westin, Martin Lagging, et al.. (2014). Chronic hepatitis C in Swedish subjects receiving opiate substitution therapy—Factors associated with advanced fibrosis. Scandinavian Journal of Infectious Diseases. 46(5). 340–347. 5 indexed citations

10.

Jerkeman, Anna, Jan Astermark, Ulla Hedner, et al.. (2000). Correlation between Different Intensities of Anti-Vitamin K Treatment and Coagulation Parameters. Thrombosis Research. 98(6). 467–471. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact